Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity
- 2 August 2019
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 4 (38)
- https://doi.org/10.1126/sciimmunol.aav6473
Abstract
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a first-line therapy for rapidly killing tumors such as those associated with non–small cell lung cancer by blocking oncogenic receptor signaling, but tumor relapse often occurs. Here, we have observed that hypofractionated EGFR TKI treatment (HypoTKI) is more potent than standard hyperfractionated EGFR TKI treatment (HyperTKI), and its antitumor effect associated with preventing tumor relapse depends on T cells. HypoTKI triggers greater innate sensing for type I IFN and CXCL10 production through the Myd88 signaling pathway to enhance tumor-specific T cell infiltration and reactivation. We also demonstrate that timely programmed cell death ligand–1 (PD-L1) blockade can synergize with HypoTKI to control advanced large tumors and effectively limit tumor relapse without severe side effects. Our study provides evidence for exploring the potential of a proper combination of EGFR TKIs and immunotherapy as a first-line treatment for treating EGFR-driven tumors.Funding Information
- National Cancer Institute (CA141975)
This publication has 58 references indexed in Scilit:
- Targeting the EGFR signaling pathway in cancer therapyEmerging Therapeutic Targets, 2012
- The confluence of radiotherapy and immunotherapyFrontiers in Oncology, 2012
- Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cellsBritish Journal of Cancer, 2011
- Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer ModelingScience Translational Medicine, 2011
- Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapyProceedings of the National Academy of Sciences of the United States of America, 2011
- Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathwayToxicology and Applied Pharmacology, 2011
- Resiliency and Vulnerability in the HER2-HER3 Tumorigenic DriverScience Translational Medicine, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 AntibodyClinical Cancer Research, 2009
- The epidermal growth factor receptor family: Biology driving targeted therapeuticsCellular and Molecular Life Sciences, 2008